Fu Miaoxin, Lv Mingzhu, Guo Jinyue, Mei Aihua, Qian Hang, Yang Handong, Wu Wenwen, Liu Zhixin, Zhong Jixin, Wei Ying, Min Xinwen, Wu Haiyan, Chen Jun
Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, Hubei, China.
Shiyan Key Laboratory of Virology, Hubei University of Medicine, Shiyan, China.
Front Immunol. 2025 Feb 26;16:1550206. doi: 10.3389/fimmu.2025.1550206. eCollection 2025.
Hypertension, a globally prevalent condition, is closely associated with T cell-mediated inflammatory responses. Studies have shown that T cells, by secreting pro-inflammatory cytokines such as interferon-gamma (IFN-γ), Interleukin-17 (IL-17), and Tumor necrosis factor-alpha (TNF-α), directly lead to vascular dysfunction and elevated blood pressure. The activation of Th1 and Th17 cell subsets, along with the dysfunction of regulatory T cells (Tregs), is a critical mechanism in the onset and progression of hypertension. This review explores the role of T cells in the pathophysiology of hypertension and discusses potential therapeutic strategies targeting T cell regulation, such as immunotherapy and gene-editing technologies. These emerging treatments hold promise for providing personalized therapeutic options for hypertensive patients, reducing inflammatory complications, and improving treatment outcomes.
高血压是一种全球普遍存在的疾病，与T细胞介导的炎症反应密切相关。研究表明，T细胞通过分泌促炎细胞因子，如干扰素-γ（IFN-γ）、白细胞介素-17（IL-17）和肿瘤坏死因子-α（TNF-α），直接导致血管功能障碍和血压升高。Th1和Th17细胞亚群的激活，以及调节性T细胞（Tregs）的功能障碍，是高血压发病和进展的关键机制。本综述探讨了T细胞在高血压病理生理学中的作用，并讨论了针对T细胞调节的潜在治疗策略，如免疫疗法和基因编辑技术。这些新兴治疗方法有望为高血压患者提供个性化治疗选择，减少炎症并发症，并改善治疗效果。
